Summary Camptothecins are DNA topoisomerase I-directed anti-tumour drugs with a novel mechanism of action. Topotecan (TPT), a hydrophilic derivative of camptothecin, is currently undergoing phase II clinical trials in small-cell lung cancer (SCLC). Human SCLC OC-NYH cells were made more than 6-fold resistant to topotecan by stepwise drug exposure and resistance was stable for 70 passages without drug. NYH/TPT cells had half the topoisomerase I level and activity of wild-type cells. However, no difference in camptothecin or topotecan inhibition of topoisomerase I-mediated DNA relaxation was found, indicating that the enzyme itself was unchanged in the resistant cell. In NYH/TPT cells, topoisomerase IIa and P levels were increased approximately 2-fold. Accordingly, the topoisomerase II-directed drug etoposide (VP-16) induced an increased number of DNA single-strand breaks in NYH/TPT cells. However, sensitivity to different topoisomerase Il-targeting agents in NYH/TPT cells varied from increased to decreased, indicating a role for as yet unidentified factors acting on the pathway to cell death after topoisomerase TI-induced DNA damage has occurred. Of 20 anti-cancer agents tested, only hydroxyurea showed marked collateral hypersensitivity in NYH/TPT cells.
Topoisomerase I is a nuclear enzyme which catalyses the relaxation of supercoiled DNA by introducing transient DNA single-strand breaks (SSBs). Camptothecin (CPT), a topoisomerase I-targeting drug, is active against several experimental tumours. The drug interferes with the breakage-reunion reaction by stabilising an enzyme-DNA intermediate, termed the cleavable complex (Liu, 1989) . Considerable interest has been directed towards topoisomerase I-active compounds as they represent a novel target for anti-tumour drugs. As camptothecin is too toxic for clinical use, several semisynthetic hydrophilic derivatives of camptothecin have been developed. Among these, the charged derivative topotecan (TPT, 9-dimethyl-amino-methyl-10-hydroxycamptothecin) is currently undergoing phase II clinical trials (Slichenmeyer et al., 1993) . Several cell lines have been selected for primary camptothecin and CPT-l1 [7-ethyl-10-[4- (1-piperidino)-1-piperidino]carbonyl-oxycamptothecin] resistance, both in vivo and in vitro, by stepwise continuous exposure or by mutagenic treatment. A major feature of resistance towards these agents is a reduced extractable topoisomerase I activity reflecting a reduced content of the enzyme. In addition, some camptothecin-resistant cell lines display an altered topoisomerase I which is resistant to inhibition of catalytic activity by camptothecin and is frequently associated with a point mutation of the topoisomerase I gene (Andoh et al., 1987; Gupta et al., 1988; Tan et al., 1989; Eng et al., 1990; Kanzawa et al., 1990; Sugimoto et al., 1990a; Chang et al., 1992; Kubota et al., 1992; Woessner et al., 1992; Madelaine et al., 1993) . Cell lines with primary resistance to topotecan have not, to our knowledge, previously been described in detail. Phase II trials of topotecan in small-cell lung cancer (SCLC) are currently in progress, and the purpose of our study was therefore to describe possible mechanisms of resistance towards this promising new drug in a human SCLC cell line. by comparing with freshly diluted drug in a clonogenic assay. All drugs were checked in this setting.
Materials and methods

Materials
Cell lines
The human SCLC cell line OC-NYH (also designated GLC-2) grows as a loosely attached monolayer in RPMI-1640 medium supplemented with 10% fetal calf serum plus penicillin, streptomycin and L-glutamine at 37°C in a humidified atmosphere with 7.5% carbon dioxide (Leij et al., 1985) . The topotecan-resistant subline NYH/TPT was established by exposing OC-NYH cells to increasing concentrations of drug over 1 year (54 passages) and was maintained at 38 nM topotecan. The resistance was stable after 70 passages without drug. In order to avoid genetic drift, the cell lines used in experiments were re-established from frozen stocks at regular intervals. Cell lines regularly tested negative for mycoplasma contamination.
Clonogenic assay Drug sensitivity was assessed by colony formation in soft agar with a feeder layer containing sheep red blood cells as previously described (Roed et al., 1987 Preparation of whole-cell lysate All steps were performed at 4°C. Exponentially growing cells were harvested and washed twice in phosphate buffered saline (PBS; 2.67 mM potassium chloride, 137 mM sodium chloride, 1.45 mM sodium dihydrogen phosphate, 6.45 mM disodium hydrogen phosphate, pH 7.4) supplemented with 1 mM benzamidine (Sigma), 1 mM Phenyl methyl sulphonyl fluoride (PMSF, Sigma) and 10 yg ml-' soybean trypsin inhibitor (Sigma). Cells were lysed with 0.2% SDS and digested with 500 units ml-' Benzon nuclease (Alfred Benzon, Denmark). An equal volume of 9 M urea, 4% (v/v) NP-40 and 2% (v/v) P-mercaptoethanol was added. Lysates were used immediately after preparation.
Preparation of crude nuclear extracts Crude nuclear extracts were performed by a modification of a previously described method (Deffie et al., 1989) . All steps were performed at 4°C. Exponentially growing cells were harvested and washed twice in nucleus buffer (NB) [2 mM potassium dihydrogen phosphate, 5 mM magnesium chloride, 150 mm sodium chloride, 1 mM EGTA and 0.2 mM dithiothreitol (DTT), 1 mM PMSF, pH 6.5). Cells were resuspended in 1 ml of NB and were lysed for 5 min by gently adding 9 ml of NB supplemented with 0.3% (v/v) Triton X-100. Nuclear pellets were spun down at 1000 g for 10 min and washed with NB. Proteins were extracted for 30 min in NB with 350 mM sodium chloride. Insoluble nuclear fragments were spun down at 17 000 g and the supernatant was collected. Extracts were diluted in an equal volume of glycerol and stored at -80°C. Protein concentrations were measured by the Bradford protein assay (Bradford, 1976 Table  II. DNA topoisomerase I activity To ascertain whether resistance was related to an alteration in topoisomerase I activity level, the catalytic activity in nuclear extracts was measured. As shown in Figure 1 , the topoisomerase I activity in NYH/TPT extracts was reduced to about half that of OC-NYH. We also examined whether equal amounts of enzyme in extracts from the resistant cells had altered sensitivity to the inhibitory effect of camptothecin and topotecan compared with wild-type cells. At camptothecin concentrations of 5, 10 and 50 gLM (data not shown) and topotecan concentrations of 25, 200 and 500 lLM (Figure   2 ), inhibition of topoisomerase I activity in NYH/TPT cells was similar to that of OC-NYH cells, indicating that no qualitative alteration had occurred in the topoisomerase I enzyme in this cell line.
Content of immunoreactive DNA topoisomerase I and IIoa and
The amount of topoisomerase I and IIa in nuclease-treated whole-cell lysate and topoisomerase I and Ila and P in nuclear extracts was measured by Western blotting in order to determine whether quantitative reduction of the target enzyme was responsible for the reduced topoisomerase I activity. As shown in Figure 3a , the levels of immunoreactive topoisomerase I in whole-cell lysates from NYH/TPT cells were reduced compared with the wild-type level. and 8, 0.5 jig of nuclear extract; lanes 5 and 9, 0.3 iLg of nuclear extract; lanes 6 and 10, 0.2 tLg of nuclear extract. extracts, topoisomerase I levels were 0.4-0.6 in NYH/TPT cells, while topoisomerase IIa levels were 1.6 to 3.0-fold (data not shown) and topoisomerase I1p levels were 2.0-fold increased in NYH/TPT compared with OC-NYH cells ( Figure  4) 
Discussion
As camptothecins represent a class of anti-cancer agents with a novel mechanism of action, considerable efforts are currently directed towards the determination of the optimal scheduling of these new compounds in cancer therapy. One way of addressing this problem is to evaluate which mechanism(s) of resistance the tumour cells will avail themselves of. Topotecan and CPT-1 1 (irinotecan) are the two topoisomerase I-directed drugs which are currently undergoing phase II clinical trials. To our knowledge, the present cell line is the first topotecan-resistant cell line that has been characterised in detail, a resistance that was remarkably stable, being hardly reduced by 70 passages without drug. However, several camptothecin-resistant cell lines have been described. The most common feature associated with camptothecin resistance is a reduced topoisomerase I activity as a result of either a reduction in the content of the enzyme or a mutation in the enzyme which renders itself less sensitive to drug, or a combination of both (Andoh et al., 1987; Gupta et al., 1988; Eng et al., 1990; Kanzawa et al., 1990; Chang et al., 1991; Kubota et al., 1992; Tanizawa and Pommier, 1992; Madelaine et al., 1993) . NYH/TPT therefore resembles camptothecin-resistant cells in reduction in target activity.
Several observations indicate that camptothecin is not a substrate for the P-glycoprotein efflux pump (Naito et Chen et al., 1991) . However, it has been shown that cytotoxicity and accumulation of topotecan are reduced in P-glycoprotein-overexpressing cells, and topotecan is believed to be a weak substrate for P-glycoprotein (Hendricks et al., 1992) . It is therefore of interest that the NYH/TPT cells showed no evidence of P-glycoprotein overexpression.
A major point in establishing a resistant cell line is to determine its cross-resistance pattern, as this may have clinical implications. Cellular resistance to topoisomerase I drugs in cells with an unaltered or increased level of topoisomerase II has been associated with an increased sensitivity to topoisomerase II-targeting agents in several studies (Gupta et al., 1988; Tan et al., 1989; Oguro et al., 1990; Chang et al., 1991) . This inverse sensitivity pattern of topoisomerase I and II poisons could be caused by increased dependence on topoisomerase II in cells with a deficient topoisomerase I. The NYH/TPT line does indeed have a marked increase in topoisomerase Ila and 1B content as well as an increase in VP-16-induced SSBs. Further, we observed that the increase in topoisomerase II levels is an early event, occurring before the reduction in topoisomerase I, indicating a need to compensate for damaged topoisomerase I functions ( Figure 5 ). However, it is curious that NYH/TPT cells were cross-resistant to both mitoxantrone and m-AMSA, especially as the number of m-AMSA-induced SSBs was increased in NYH/TPT cells (data not shown). Also, given the high expression of topoisomerase II and increased number of SSBs caused by VP-16 in NYH/TPT, one would have expected a more marked hypersensitivity to VP-16 in this subline, as suggested by studies on CHO cells (Davies et al., 1988) . A similar cross-resistance to doxorubicin, VP-16 and m-AMSA in spite of a marked increase in topoisomerase II levels was found in A549/CPT cells (Sugimoto et al., 1990b) . Further, CPT-11-resistant cells with lack of crossresistance or slight hypersensitivity to VP-16 and VM-26 also demonstrate slight cross-resistance to doxorubicin (Kanzawa et al., 1990) . Thus, the relationship between topoisomerase II levels and sensitivity to topoisomerase II-targeting agents in topoisomerase I-resistant cell lines is complex, and presumably other, as yet unidentified, factors act on the pathway to cell death after topoisomerase 11-induced DNA damage has occurred in NYH/TPT cells. Cross-resistance to alkylating agents, as shown in Table II , varied from marked (cisplatin, melphalan and mitomycin C) to none (BCNU) . No cross-resistance (Kanzawa et al., 1990) or slight hypersensitivity (Oguro et al., 1990) to cisplatin has been reported in cell lines resistant to camptothecin analogues. In this context, it is interesting that a melphalan-resistant cell line has decreased topoisomerase I and is cross-resistant to topotecan (Friedman et al., 1994) . On the other hand, hypersensitivity to CPT-11 associated with increased topoisomerase I was seen in cisplatin-resistant cells (Kotoh et al., 1994) . These data indicate that there is no straightforward relationship between sensitivity to topoisomerase I-targeting agents and alkylating agents. Hydroxyurea was the only drug tested with marked collateral hypersensitivity (Table II) . This could be due to increased DNA repair as suggested by the crossresistance to cisplatin, a finding which merits further study as to its mechanism.
